All articles by Vishnu Priyan

Rigel enrols first participant in Phase Ib/II AML treatment regimen trial

Rigel Pharmaceuticals has announced the enrolment of the first subject in a Phase Ib/II clinical trial of REZLIDHIA (olutasidenib) in…
Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases

Aurinia Pharmaceuticals has dosed the first subject in a Phase Ia single ascending dose (SAD) clinical trial of AUR200, as…
Boehringer and CDR-Life report data from geographic atrophy treatment trial

Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new treatment…
Lilly’s efsitora shows promise in Phase III type 2 diabetes trials

Eli Lilly and Company has revealed positive topline results from the Phase III clinical trials of once-weekly insulin efsitora alfa…
FDA grants IND clearance for Adaptin Bio’s Phase I glioblastoma therapy trial

The US Food and Drug Administration (FDA) has granted clearance for an Investigational New Drug (IND) application of Adaptin Bio,…

WashU Medicine finds anti-clotting drugs fail to improve stroke care outcomes

Researchers at the Washington University School of Medicine (WashU Medicine) in the US have found that adding anti-clotting stroke drugs…
Vesper Bio reports data from Phase I frontotemporal dementia treatment trial

Vesper Bio has reported data from a Phase I study of VES001, a potential disease-modifying treatment for frontotemporal dementia (FTD),…
MSD and EyeBio launch trial of Restoret for diabetic macular oedema

MSD (Merck & Co) and its wholly-owned subsidiary EyeBio have announced the start of the Phase IIb/III BRUNELLO clinical trial…
Evommune enrols first subject in chronic inducible urticaria therapy trial

Evommune has enrolled the first subject in a Phase II clinical trial of EVO756 designed to treat adults with chronic…
Avenzo and Gilead partner for breast cancer combination regimen trial

Avenzo Therapeutics has announced a clinical trial partnership and supply agreement with Gilead Sciences to assess a combination treatment regimen…